Followers | 10 |
Posts | 1467 |
Boards Moderated | 0 |
Alias Born | 07/16/2006 |
Saturday, November 22, 2014 6:38:31 PM
_____________________________________________________________
increasingly disgruntled investors the board just isn't fun to read anymore
_______________________________________________________________
It seems to me there are two camps using this board.
One camp usually/always presents a negative point of view and keeps looking in a distant rear view mirror. This camp has 6 at most posters, some of who are suspected of using multiple alias.
This camp is what makes the board hard to read as there are so many rebuttals that distract from the facts.
The other camp is way bigger and have many more forward looking positive points of view.
For example:
6,000+ tested animals with only positive, for NNV,C results.
A new Plant being certified NOW. Built in the last year. A state of the art facility. Expected to be open in 1/2015. Capacity to greatly increase from 200gs per batch in the Wood street lab.
Lab reports ( all labs are independent of NNVC) that show Flucide is 1,500x more effective than Tamiflu. All subject animals survived with Flucide (sacrificed after 28 days and not toxicity found)vs dead after 8 days(Tamiflu) or 5days untreated. BASi now doing toxicity testing with "NO BAD NEWS" REPORTED TO DATE! This daily non reporting translates to good news.
See post from changes_iv for a better list of a programs underway.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM